$46.48
-0.38-0.81%
At close: Aug 28, 5:00 PM EST
$46.48
N/A
After Hours: 4:00 PM EST
Rigel Pharmaceuticals Inc
RIGLNASDAQ
Rigel Pharmaceuticals Earnings & Forecasts
Rigel Pharmaceuticals (RIGL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Rigel Pharmaceuticals Guidance
Rigel Pharmaceuticals (RIGL) last issued guidance on August 4, 2026 for fiscal year 2026. The company guided revenue in the range of $285M - $295M for the period.
Compared to prior guidance, Rigel Pharmaceuticals raised its revenue forecast from a prior range of $275M - $290M.
Rigel Pharmaceuticals has issued 15 guidance updates between January 9, 2023 and August 4, 2026. During this period, the company raised its outlook 7 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.17 | $0.85 | $1.25 | $0.85 |
| Actual | $0.88 | $0.44 | $1.12 | $1.46 |
| Surprise | +417.6% | -48.2% | -10.4% | +71.8% |
| Revenue | ||||
| Estimate | $58.6M | $62.0M | $69.1M | $61.8M |
| Actual | $78.7M | $58.8M | $69.8M | $69.5M |
| Surprise | +34.2% | -5.11% | +0.95% | +12.5% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.94 | $1.02 | $0.49 | $0.80 |
| Revenue | ||||
| Consensus | $79.7M | $87.1M | — | — |
